Search clinical trials for: CHF1535 pMDI

Total 343 results

Integrum
University Medical Center Groningen; Sahlgrenska University Hospital, Sweden; National University of Ireland, Galway, Ireland and other collaborators

Completed

Phantom Motor Execution Via MPR, VR/AR, and SG, as a Treatment of PLP

Phantom Limb Pain

United States, Canada, Ireland, Netherlands, Slovenia, Sweden, Germany
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
Melissa Marchand

Completed

Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED (PMD-MSC-ED-01)

Erectile Dysfunction

United States
AstraZeneca

Recruiting

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (VATHOS)

Asthma

United States, Canada, Italy, Japan, Vietnam, Spain, Germany, Malaysia
Chiesi Farmaceutici S.p.A.

Completed

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) (FLASH)

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Medasense Biometrics Ltd

Completed

Performance Assessment of the PMD-200 in Subjects Requiring Surgery Under General Anesthesia

Anesthesia

Israel
Medasense Biometrics Ltd

Terminated

Evaluation of Medasense's PMD-200 During Surgery and Post Anesthesia Care

Postoperative Pain | Surgery | Nociceptive Pain

Israel
Neutec Ar-Ge San ve Tic A.Ş

Withdrawn

Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD

Chronic Obstructive Pulmonary Disease
Chiesi Farmaceutici S.p.A.

Completed

BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)

Pulmonary Disease, Chronic Obstructive

United Kingdom
Azienda Ospedaliero-Universitaria Careggi

Completed

Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes

Diabetes Mellitus, Type 1

Italy
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Asthma

United States
AstraZeneca

Recruiting

A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS) (LITHOS)

Asthma

United States, Canada, South Africa, Korea, Republic of, Philippines, Czechia, Malaysia, Germany
LMC Diabetes & Endocrinology Ltd.
Insulet Corporation

Completed

Canadian Real-World Outcomes of Omnipod Initiation in People With T1D (COPPER)

Diabetes Mellitus, Type 1

Canada
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

Asthma

United States
GlaxoSmithKline

Completed

Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

Asthma

Japan
Boehringer Ingelheim

Completed

The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers

Healthy
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

Bronchial Asthma

Spain, Italy, Russian Federation, Ukraine
AstraZeneca

Completed

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Asthma

United States, Puerto Rico
Chiesi Farmaceutici S.p.A.

Completed

A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients. (ADONE)

Asthma

United Kingdom, Denmark
European Institute of Oncology
Associazione Italiana per la Ricerca sul Cancro

Completed

Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer (InForma)

Breast Cancer

Italy
National Institute of Medical Sciences and Nutrition...

Recruiting

Distress Related to the Feeling of Loss of Dignity in Patients With Rheumatic Diseases

Quality of Life | Rheumatic Diseases | Dignity | Distress, Emotional

Mexico
Rabin Medical Center
The Leona M. and Harry B. Helmsley Charitable Trust; DreaMed Diabetes

Recruiting

Evaluation of a Decision Support System for People With Diabetes Who Use Multiple Daily Insulin Injections- Feasibility and Proof of Concept Studies

Type1diabetes

Israel
Medasense Biometrics Ltd

Terminated

Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit

Anesthesia, General

Israel
AstraZeneca
Simbec Research

Completed

A Scintigraphy Study of PT010 in COPD Patients (RD708/34000)

Chronic Obstructive Pulmonary Disease

United Kingdom
Organon and Co

Completed

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)

Asthma
Chiesi Farmaceutici S.p.A.
SGS S.A.

Recruiting

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Asthma

Belgium
University of Illinois at Urbana-Champaign
University of Washington

Not yet recruiting

Peer MI in FQHCs for Substance-using Emerging Adults

Substance Use Disorders

United States
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
University Hospital, Antwerp
Universiteit Antwerpen; York University

Not yet recruiting

cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances (ACT-ONE)

Diabetes Mellitus, Type 1
AstraZeneca

Completed

Titratable Dosing in Moderate to Severe Asthmatics

Asthma
AstraZeneca

Completed

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

Asthma

United States
Assiut University

Unknown

PDIUC Protocol for Placental Accreta (PDIUC)

Placenta Accreta
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Asthma
Medasense Biometrics Ltd

Completed

Impact of NOL Intraoperative Guided Fentanyl Analgesia vs SCC for Elective Major Abdominal Surgery

Anesthesia

Israel
AstraZeneca

Completed

Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma (Spacer)

Asthma

Russian Federation, Hungary, Poland
Sunovion

Completed

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

Asthma

United States
William Beaumont Hospitals

Completed

Impact of Pharmacy Clinic on Diabetes Management (PharmaMD)

Diabetes Mellitus, Type 2

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Sunovion

Completed

Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (Neptune)

Asthma

Poland
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Korea, Republic of, Argentina, Canada, India, Bulgaria, Poland
Bond Avillion 2 Development LP

Completed

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (DENALI)

Asthma

United States, Germany, Ukraine, Serbia, Czechia, Argentina, Slovakia
Shanghai Medinno Pharmaceutical Technology Co.,...

Recruiting

A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults

Allergic Conjunctivitis

Australia
AstraZeneca

Completed

PreAsthmaControl (PAC)

Asthma

Denmark
Hospices Civils de Lyon

Completed

Validation of the Hospital Frailty Score in France (HFRS France)

Frailty | Elderly | Emergency Hospitalization

France
Chiesi Farmaceutici S.p.A.

Completed

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers (CT14)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

PT003 MDI Cardiovascular Safety Study

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Sunovion

Completed

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

Asthma

United States

3

Subscribe